Send to

Choose Destination
See comment in PubMed Commons below
P T. 2012 Jul;37(7):405-11.

Hydroxyprogesterone caproate injection (makena) one year later: to compound or not to compound that is the question.


Preterm births have increased by 27% over the last decade in the U.S. The main ingredient in Makena, 17P, is less expensive at compounding pharmacies, but this method is not FDA-approved. The authors discuss the quality, safety, and use of Makena and compounded 17P; the potential for liability; cost considerations; and recommended restrictions for the product's use.

PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Write to the Help Desk